Medical Pharmacology Chapters 33-34 Hydroxyurea

Choose the correct statement/statements concerning hydroxyurea:
1. Classified as an antimetabolite
2. Prevents conversion of ribonucleotides to deoxyribonucleotides.
3. Both
4. Neither
Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase.
1. True
2. False
Hydroxyrurea:
1. Stops the cell-cycle at the G1/S phase.
2. Exibits radiation sensitizing activity
3. Both
4. Neither
Hydroxyurea is classified as an antileukemic drug.
1. True
2. False
In sickle cell anemia:
1. Hydroxyrurea increases hemoglobin F levels
2. Red blood cell water content
3. Deformability of sickled cells
4. Changes the character of red blood cell adhesion to the endothelium
5. A & B
6. B & C
7. A & C
8. A, B, C & D
9. D
Concerning hydroxyurea pharmacokinetics/pharmacodynamics:
1. Rapid and readily absorbed
2. Widely distributed throughout the body; volume of distribution is about the same as total body water.
3. Drug concentrates in erythrocytes and leukocytes
4. Metabolism involves their metabolism and urease (intestinal bacteria)
5. A & B
6. B & D
7. All responses (A, B, C & D) are correct
Hydroxyrurea administration results in substantial drug appearing in human breast milk.
1. True
2. False
In patients with renal dysfunction, changes in initial dosing appears indicated.
1. True
2. False
Clinical use/uses:
1. Chronic myeloid leukemia (resistant)
2. Head and neck cancer
3. Sickle cell anemia
4. All of the above
Primary use of hydroxyrurea: Myelosuppressive drug for management of myeloproliferative disease.
1. True
2. False
Clinical uses of hydroxyurea includes/includes:
1. Chronic myelogenous leukemia (CML)
2. Myeloid metaplasia
3. Polycythemia
4. Essential thrombocytosis
5. A & B
6. B & C
7. A, B, C & D
Principal hydroxyrurea adverse effects/effects:
1. Leukopenia
2. Occasional thrombocytopenia
3. Anemia
4. All the above
Hydroxyurea exibits strata genicity in animal models and should not be used in women who may bear children.
1. True
2. False